Associated Papers
Concurrent Coprimary KIT Exon 17 and BRAF Mutations in a Small Intestinal GI Stromal Tumor-A Case Report.
Ishfaq H et al.
Journal of Gastrointestinal Cancer, 2025
Characteristics of germline DNA damage response gene mutations in ovarian cancer in Southwest China.
Fu K et al.
Scientific Reports, 2024
38509102 (PubMed )
Supplement: 41598_2024_52707_MOESM2_ESM.xlsx › mutation
Predicted deleterious variants in the human genome relevant to gene therapy with adeno-associated virus vectors.
Rostami MR et al.
Molecular Therapy. Methods & Clinical Development, 2023
38089635 (PubMed )
Supplement: mmc2.xlsx › Supplemental_Table_II
A literature review and database of how the primary KIT/PDGFRA variant of a gastrointestinal stromal tumour predicts for sensitivity to imatinib.
Wong NACS et al.
Cancer Genetics, 2022
Progression of the tumor in a patient with a gastrointestinal stromal tumor with the PDGFRA exon 12 mutation who received multiple surgeries and multiple lines of tyrosine kinase inhibitor therapies: a case report.
An Z et al.
Journal of Gastrointestinal Oncology, 2022
Type and Gene Location of KIT Mutations Predict Progression-Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the Exon.
Incorvaia L et al.
Cancers, 2021
KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors.
Miranda C et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2012
Epidemiology and molecular biology of gastrointestinal stromal tumors (GISTs): a population-based study in the South of Switzerland, 1999-2005.
Mazzola P et al.
Histology and Histopathology, 2008
Select a paper to view details